Sunday, Sep 19, 2021 | Last Update : 11:03 PM IST

  India   All India  01 Jul 2021  Zydus Cadila applies for emergency use nod for COVID-19 vaccine

Zydus Cadila applies for emergency use nod for COVID-19 vaccine

REUTERS
Published : Jul 1, 2021, 9:06 am IST
Updated : Jul 1, 2021, 9:06 am IST

ZyCoV-D showed safety and efficacy in a late-stage trial with more than 28,000 volunteers, including subjects in the 12-18 year age group

An approval for Zydus' vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in India. (Representational image: AP)
 An approval for Zydus' vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in India. (Representational image: AP)

Bengaluru: Indian drugmaker Zydus Cadila (CADI.NS) said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.

Coronavirus cases in India dropped from a devastating peak in April and May, however, experts have warned of a third wave and reiterated that widespread vaccination remains one of the best defences against the pandemic.

 

An approval for Zydus' vaccine, ZyCoV-D, would make it the fifth vaccine authorized for use in India, after Moderna, AstraZeneca (AZN.L) and partner Serum Institute of India's Covishield, Bharat Biotech's Covaxin, and Sputnik V developed by Russia's Gamaleya Institute.

ZyCoV-D showed safety and efficacy in a late-stage trial with more than 28,000 volunteers across the country, including about 1,000 subjects in the 12-18 year age group, Zydus said.

The study was carried out "during the peak of second wave of COVID-19 (in India), reaffirming the vaccine's efficacy against the new mutant strains especially the Delta variant," Zydus said in a statement to the stock exchanges.

 

Tags: zydas cadila healthcare ltd, covid vaccine, drug regulator, drug maker
Location: India, Karnataka, Bengaluru